Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
Q1 2026 vs. Q4 2025
How the institutions holding Innate Pharma SA changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 11 | 9 | −2 |
| Shares | 276.3K | 184.0K | −92.3K (−33.4%) |
| Value | $483.5K | $235.5K | −$248.0K (−51.3%) |
New holders (1)
Institutions that held Innate Pharma SA at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Caitong International Asset Management Co., Ltd | 2 | $3 | 0.00% |
Sold out (3)
Institutions that held Innate Pharma SA at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Old Mission Capital LLC | 28,431 | $49.8K |
| Barclays PLC | 1 | $2 |
| SageView Advisory Group, LLC | 1 | $2 |